project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9LU; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.27; rna integrity number: 7.8; age at index: 67; days to birth: -24742; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1945; age at diagnosis: 24742; ajcc clinical m: M0; ajcc clinical t: T2b; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 579.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 617; initial weight: 380.0; sample id: ded8e46f-e309-4ff1-aee0-85bab613cc00; sample submitter id: TCGA-ZG-A9LU-01A; portion id: 70e84b8a-963a-4b48-abcb-b8fb0afac9c9; portion submitter id: TCGA-ZG-A9LU-01A-11; slide id: 255c0b9f-a490-48b7-a4ee-709493f565e2; slide submitter id: TCGA-ZG-A9LU-01A-01-TSA; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 70.0; section location: TOP;